Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Myelofibrosis (MIPSS70+2.0 MF)
NCT05447260Phase 4Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ruxolitinib in myelofibrosis (MF), sponsored by Qilu Hospital of Shandong University. Status: unknown.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05447260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05447260.